Anti-Inflammatory Effect of IKK-Activated GSK-3 beta Inhibitory Peptide Prevented Nigrostriatal Neurodegeneration in the Rodent Model of Parkinson's Disease
Anti‐Inflammatory Effect of IKK‐Activated GSK‐3β Inhibitory Peptide Prevented Nigrostriatal Neurodegeneration in the Rodent Model of Parkinson’s Disease
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES23(2) · 2022
- 피인용
- Web of Science 12Scopus 12
- FWCI (Scopus)
- 0.75
- JCR IF
- JCR 2021 6.208
- ISSN
- 1661-6596
저자
- 이슬아제1저자Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
- 홍동근Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
- 양성욱Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
- 김재훈Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
- 백민우Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
- 김서영Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
- 띠루말라이 디나카란Pusan Natl Univ, Dept Cognomechtron Engn, Coll Nanosci & Nanotechnol, Busan 46241, South Korea
- 정해영Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
- 장승철Pusan Natl Univ, Dept Cognomechtron Engn, Coll Nanosci & Nanotechnol, Busan 46241, South Korea
- 이재원교신저자Pusan Natl Univ, Dept Pharm, Coll Pharm, Busan 46241, South Korea
초록
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.Parkinson’s disease (PD) is a progressive movement disorder caused by nigrostriatal neu-rodegeneration. Since chronically activated neuroinflammation accelerates neurodegeneration in PD, we considered that modulating chronic neuroinflammatory response might provide a novel therapeutic approach. Glycogen synthase kinase 3 (GSK‐3) is a multifunctional serine/threonine protein kinase with two isoforms, GSK‐3α and GSK‐3β, and GSK‐3β plays crucial roles in inflammatory response, which include microglial migration and peripheral immune cell activation. GSK‐ 3β inhibitory peptide (IAGIP) is specifically activated by activated inhibitory kappa B kinase (IKK), and its therapeutic effects have been demonstrated in a mouse model of colitis. Here, we investi-gated whether the anti‐inflammatory effects of IAGIP prevent neurodegeneration in the rodent model of PD. IAGIP significantly reduced MPP⁺‐induced astrocyte activation and inflammatory response in primary astrocytes without affecting the phosphorylations of ERK or JNK. In addition, IAGIP inhibited LPS‐induced cell migration and p65 activation in BV‐2 microglial cells. In vivo study using an MPTP‐induced mouse model of PD revealed that intravenous IAGIP effectively prevented motor dysfunction and nigrostriatal neurodegeneration. Our findings suggest that IAGIP has a cu-rative potential in PD models and could offer new therapeutic possibilities for targeting PD.
키워드
1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridineAnti‐inflammationInhibitory κB kinase‐activated GSK‐3β inhibitory peptideNeuroinflammationParkinson’s diseaseGLYCOGEN-SYNTHASE KINASE-3GSK3 INHIBITORSTNF-ALPHAKAPPA-B
식별자
- Scopus EID
- 2-s2.0-85122816060
- WoS UID
- 000758577600001



로그인
연구물 목록으로